Judith M Bliss
Overview
Explore the profile of Judith M Bliss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
5621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coles C, Haviland J, Kirby A, Griffin C, Sydenham M, Bliss J
Lancet
. 2024 May;
403(10438):1752.
PMID: 38704171
No abstract available.
2.
Coles C, Earl H, Anderson B, Barrios C, Bienz M, Bliss J, et al.
Lancet
. 2024 Apr;
403(10439):1895-1950.
PMID: 38636533
No abstract available.
3.
Sydes M, Murray M, Ahmed S, Apostolidou S, Bliss J, Bloomfield C, et al.
Contemp Clin Trials
. 2024 Mar;
141:107514.
PMID: 38537901
Background: Better use of healthcare systems data, collected as part of interactions between patients and the healthcare system, could transform planning and conduct of randomised controlled trials. Multiple challenges to...
4.
Brunt A, Haviland J, Wheatley D, Sydenham M, Bloomfield D, Chan C, et al.
Health Technol Assess
. 2023 Nov;
27(25):1-176.
PMID: 37991196
Background: FAST-Forward aimed to identify a 5-fraction schedule of adjuvant radiotherapy delivered in 1 week that was non-inferior in terms of local cancer control and as safe as the standard...
5.
Kingston B, Pearson A, Herrera-Abreu M, Sim L, Cutts R, Shah H, et al.
Cancer Discov
. 2023 Nov;
14(2):274-289.
PMID: 37982575
Significance: Novel F404 ESR1 mutations may be acquired to cause overt resistance to fulvestrant when combined with preexisting activating ESR1 mutations. Novel combinations of mutations in the ER ligand binding...
6.
Velikova G, Morden J, Haviland J, Emery C, Barrett-Lee P, Earl H, et al.
Lancet Oncol
. 2023 Nov;
24(12):1359-1374.
PMID: 37926100
Background: Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time...
7.
Ring A, Kilburn L, Pearson A, Moretti L, Afshari-Mehr A, Wardley A, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4751-4759.
PMID: 37773077
Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous...
8.
Goodwin P, Chen B, Gelmon K, Whelan T, Ennis M, Lemieux J, et al.
J Clin Oncol
. 2023 Sep;
41(35):5356-5362.
PMID: 37695982
JCO Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 randomized adjuvant breast cancer trial, metformin ( placebo) did not affect invasive disease-free...
9.
Schuster E, Lopez-Knowles E, Alataki A, Zabaglo L, Folkerd E, Evans D, et al.
Nat Commun
. 2023 Jul;
14(1):4017.
PMID: 37419892
Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of...
10.
Coles C, Haviland J, Kirby A, Griffin C, Sydenham M, Titley J, et al.
Lancet
. 2023 Jun;
401(10394):2124-2137.
PMID: 37302395
Background: A tumour-bed boost delivered after whole-breast radiotherapy increases local cancer-control rates but requires more patient visits and can increase breast hardness. IMPORT HIGH tested simultaneous integrated boost against sequential...